Regeneron, Bayer extend testing of eye disease treatment
-
- March
- 27
Regeneron Pharmaceuticals Inc. of Eastview and Germany-based Bayer HealthCare AG said this morning that testing of a possible treatment for an eye disease showed the product reduced retinal thickness and improved eyesight.
The companies said they plan to begin the next phase of testing of the VEGF Trap-Eye during the second half of the year.
The companies have an agreement to develop the product for the treatment of a condition known as wet AMD, an age-related degeneration, and other eye problems.
Regeneron shares were trading at $21.93, up $2.78 or 14.5 percent at 10:17 this morning.
This entry was posted
on Tuesday, March 27th, 2007 at 10:35 am by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Print
| 
Email
